This Week at Peak Human: Your Lp(a) Is High and the First Drug Just Failed, Plus BPC-157's Real Evidence and the 10,000-Step Myth

A note from Dr. Goel

This week I want to walk you through what's actually new on peakhuman.ai, because there's a lot: our team published four new evidence reviews and refreshed one of our intervention pages with new 2026 data. The headline story is the one I think matters most for anyone tracking their own numbers — the first large outcomes trial of a targeted Lp(a)-lowering drug just reported, and the result isn't the one anyone was hoping for. Here's what changed this week, and what I think it means for you.

— Dr. Sanjeev Goel

What's new at Peak Human this week

Your Lp(a) Is High — and the First Drug Just Failed

We published a new evidence review on Lp(a)HORIZON, the first large outcomes trial of a targeted Lp(a)-lowering drug. Novartis's pelacarsen lowered Lp(a) across all 8,323 enrolled patients but did not reduce the composite of cardiovascular death, heart attack, stroke, or urgent revascularization — missing its primary endpoint. Novartis has released only topline numbers so far; the actual effect size, event counts, and detailed safety data are still being withheld pending presentation at a medical congress. Meanwhile, a separate UK Biobank analysis of 237,729 people that we cite in the piece found a 50% higher revascularization rate above an Lp(a) of 105 nmol/L — so the biomarker's relevance hasn't gone away, only the first drug aimed squarely at it has stumbled. Three rival Lp(a)-lowering drugs (lepodisiran, olpasiran, and muvalaplin) remain in Phase 3 testing.

My take: A missed primary endpoint doesn't mean Lp(a) stops mattering — it means that lowering the particle count alone, in this one trial, didn't translate into fewer events. If your Lp(a) is elevated, the levers that still matter today are aggressive LDL/apoB control and standard cardiovascular risk-factor management. I wouldn't expect a targeted Lp(a) drug on the market this year; watch the next two trial readouts before you change how you think about your own number.

What the Human Evidence on BPC-157 Actually Contains

BPC-157 is one of the most-discussed peptides in longevity and recovery circles, so we built a dedicated evidence page on what has actually been published in humans. The honest count: five published human studies, roughly 81 people in total, one of which exists only as a 2005 conference abstract. The sole human injection study used intra-articular delivery in 12 people with chronic knee pain — not the subcutaneous route used in almost every product sold today. A Phase I safety and pharmacokinetics trial in healthy volunteers was registered on ClinicalTrials.gov in 2016, and independent sources disagree on whether its results were ever submitted. This is a summary of the published research, not a safety or efficacy endorsement: BPC-157 remains investigational, several jurisdictions have moved this year to restrict it to prescription-only status, and we don't publish dosing protocols for a compound with this little human data behind it.

Plant vs Animal Protein for Muscle: Does the Source Actually Change the Result?

New on the blog: an evidence review of plant versus animal protein for building muscle. Gram for gram, plant protein isolates run lower in leucine — our piece notes you'd need roughly 54 g of hemp protein to match the leucine in 25 g of whey — and most intact plant foods digest less completely than animal protein. But when researchers matched total protein intake at 1.6–2.0 g/kg/day, vegans and omnivores gained the same 1.2 kg of leg lean mass over 12 weeks. The broader trial literature agrees: pooled data show only a modest, not clearly practical, edge for animal protein on muscle protein synthesis, and that gap narrows further once total daily dose is accounted for.

The 10,000-Step Target Came From a Product Name, Not a Study

Our newest step-count review traces where "10,000 steps" actually came from: a 1965 Japanese pedometer marketed as the Manpo-kei — literally "10,000-steps meter." The research behind it tells a flatter story than the marketing. In the cohort data we cite, walking 7,000 steps a day instead of 2,000 was associated with roughly a 47% lower rate of death from any cause — and pushing on to 10,000 steps moved the hazard ratio only from 0.53 to 0.52. Most of the benefit, in other words, arrives well before five figures.

New 2026 Data on Hyperbaric Oxygen and Cognition

We refreshed our hyperbaric oxygen therapy (HBOT) evidence page this week with new 2026 research on post-stroke cognitive outcomes that our clinical team reviewed, alongside the earlier — and still most-cited — healthy-aging telomere data. In Hachmo and colleagues' 2020 trial, 35 adults over 64 who completed 60 hyperbaric sessions showed telomere lengthening of over 20% in several immune-cell subtypes. Worth knowing: the overall repeated-measures result across all cell types in that trial was only borderline (p=0.06) — the headline gains came from specific per-cell-type comparisons, a caveat the original paper is careful about even where some press coverage wasn't. HBOT for cognition and healthy aging remains investigational and should only be pursued under qualified medical supervision after screening for contraindications.

Longevity news worth your minute

The Lp(a)-lowering race isn't over. Three competing drugs — lepodisiran, olpasiran, and the oral candidate muvalaplin — remain in Phase 3 testing after pelacarsen's miss.

BPC-157 access is tightening. Several jurisdictions moved this year to restrict BPC-157 to prescription-only status, citing exactly the thin human safety data we cover above.

Important disclaimer

This newsletter is for educational purposes only and is not medical advice. Compounds discussed may be investigational and not FDA-approved. Nothing here is a recommendation to start, stop, or change any treatment. Peptide and metabolic therapies carry real risks and should only be used under qualified medical supervision. Always consult your physician before making health decisions.